<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">Pharm Stat</journal-id><journal-id journal-id-type="iso-abbrev">Pharm Stat</journal-id><journal-id journal-id-type="pmc-domain-id">319</journal-id><journal-id journal-id-type="pmc-domain">nihpa</journal-id><journal-title-group><journal-title>Pharmaceutical statistics</journal-title></journal-title-group><issn pub-type="ppub">1539-1604</issn><issn pub-type="epub">1539-1612</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>NIHPA Author Manuscripts</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC4482106</article-id><article-id pub-id-type="pmcid-ver">PMC4482106.1</article-id><article-id pub-id-type="pmcaid">4482106</article-id><article-id pub-id-type="pmcaiid">4482106</article-id><article-id pub-id-type="manuscript-id">NIHMS689478</article-id><article-id pub-id-type="pmid">25408492</article-id><article-id pub-id-type="doi">10.1002/pst.1661</article-id><article-id pub-id-type="manuscript-id-alternative">NIHMS689478</article-id><article-id pub-id-type="manuscript-id-alternative">NIHPA689478</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Likelihood approach for evaluating bioequivalence of highly variable drugs</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Du</surname><given-names initials="L">Liping</given-names></name><xref ref-type="aff" rid="A1">a</xref><xref rid="FN1" ref-type="author-notes">*</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Choi</surname><given-names initials="L">Leena</given-names></name><xref ref-type="aff" rid="A2">b</xref></contrib></contrib-group><aff id="A1"><label>a</label>Vanderbilt Center for Quantitative Sciences, Vanderbilt University, 2525 West End, Suite 11000, Nashville TN 37203</aff><aff id="A2"><label>b</label>Department of Biostatistics, School of Medicine, Vanderbilt University, 2525 West End, Suite 11000, Nashville TN 37203</aff><author-notes><corresp id="FN1"><label>*</label>Correspondence to: Vanderbilt Center for Quantitative Sciences, Vanderbilt University, 2220 Pierce Avenue, 571 PRB, Nashville, TN 37232 <email>Liping.du@Vanderbilt.edu</email></corresp></author-notes><pub-date pub-type="epub"><day>19</day><month>11</month><year>2014</year></pub-date><pub-date pub-type="ppub"><season>Mar-Apr</season><year>2015</year></pub-date><volume>14</volume><issue>2</issue><issue-id pub-id-type="pmc-issue-id">254610</issue-id><fpage>82</fpage><lpage>94</lpage><pub-history><event event-type="nihms-submitted"><date><day>28</day><month>05</month><year>2015</year></date></event><event event-type="pmc-release"><date><day>01</day><month>03</month><year>2016</year></date></event><event event-type="pmc-live"><date><day>01</day><month>03</month><year>2016</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-06-05 14:06:38.133"><day>05</day><month>06</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2014 John Wiley &amp; Sons, Ltd.</copyright-statement><copyright-year>2014</copyright-year></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="nihms689478.pdf"/><abstract><p id="P1">Bioequivalence (BE) is required for approving a generic drug. The Two-One-Sided-Test (TOST, or the 90% confidence interval approach) has been used as the mainstream methodology to test average BE (ABE) on pharmacokinetic parameters such as the area under the blood concentration-time curve and the peak concentration. However, for highly variable drugs (%CV &gt; 30%), it is difficult to demonstrate ABE in a standard cross-over study with the typical number of subjects using the TOST due to lack of power. Recently, the US Food and Drug Administration and the European Medicines Agency recommended similar but not identical reference scaled average bioequivalence (RSABE) approaches to address this issue. Although the power is improved, the new approaches may not guarantee a high level of confidence for the true difference between two drugs at the ABE boundaries. It is also difficult for these approaches to address the issues of population BE (PBE) and individual BE (IBE). We advocate the use of a likelihood approach for representing and interpreting BE data as evidence. Using example data from a full replicate 2 &#215; 4 cross-over study, we demonstrate how to present evidence using the profile likelihoods for the mean difference and standard deviation ratios of the two drugs for the pharmacokinetic parameters. With this approach, we present evidence for PBE and IBE as well as ABE within a unified framework. Our simulations show that the operating characteristics of the proposed likelihood approach are comparable with the RSABE approaches when the same criteria are applied.</p></abstract><kwd-group><kwd>likelihood paradigm</kwd><kwd>bioequivalence</kwd><kwd>highly variable drugs</kwd><kwd>profile likelihood</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>